Latest News for REUN
-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data -- -- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 -- MORRISTOWN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the…
MORRISTOWN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in the following upcoming conferences:
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for REUN.
Senate Trading
No Senate trades found for REUN.
U.S. House Trading
No House trades found for REUN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.